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Abstract L-type pyruvate kinase gene expression is modulated
by hormonal and nutritional conditions. Here, we show by
transient transfections in hepatocytes in primary culture that
both the glucose response element and the contiguous hepatocyte
nuclear factor 4 (HNF4) binding site (L3) of the promoter were
negative cyclic AMP (cAMP) response elements and that
cAMP-dependent inhibition through L3 requires HNF4 binding.
Another HNF4 binding site-dependent construct was also
inhibited by cAMP. However, HNF4 mutants whose putative
PKA-dependent phosphorylation sites have been mutated still
conferred cAMP-sensitive transactivation of a L3-dependent
reporter gene. Overexpression of the CREB binding protein
(CBP) increased the HNF4-dependent transactivation but this
effect remained sensitive to cAMP inhibition.
z 1999 Federation of European Biochemical Societies.
Key words: L-type pyruvate kinase gene;
Cyclic AMP-dependent inhibition;
Hepatocyte nuclear factor 4
1. Introduction
The L-type pyruvate kinase (L-PK) gene encodes a key
enzyme of the glycolytic pathway; its expression is transcrip-
tionally activated by glucose and insulin and inhibited by
fasting and glucagon. This regulation has been ¢rst investi-
gated in animals; while transcriptional activation by a glu-
cose-rich diet is a slow phenomenon, requiring an active pro-
tein synthesis, inhibition by glucagon or cyclic AMP (cAMP)
analogue injection is very rapid (less than 10 min) and insen-
sitive to cycloheximide [1]. Inhibition of the L-PK gene by
glucagon has been reproduced in hepatocytes in primary cul-
ture and is mimicked by an adenylate cyclase activator and
cAMP analogues [2].
Elevation of intracellular cAMP, as a consequence of ad-
enylate cyclase activation, has been shown to regulate a vari-
ety of cellular events, including activation and repression of
gene transcription [3]. Several positive cis-acting cAMP re-
sponse elements (CRE) have been described [4]. Cyclic AMP
stimulates gene expression by activating protein kinase A
(PKA), which, in turn, phosphorylates mainly members of
the cAMP response element binding protein/activating tran-
scription factor (CREB/ATF) family of transcription factors,
thereby increasing their transactivating e⁄cacy, in particular
through interaction with coactivators [5^7]. Much less is
known about negative cis-acting cAMP-response elements.
Cyclic AMP inhibits transcription of the genes for interleu-
kin-2 (IL-2) and interleukin-2 receptor (IL-2R) in EL4 cells;
the inhibition requires an activator protein 1 (AP1) site. In
this case, cAMP increases the binding of Jun/Fos hetero-
dimers to the AP1 site and alters the composition of Jun
proteins that participate in the AP1 complex [8]. Cyclic
AMP also inhibits insulin-induced transcription of the gene
for fatty acid synthase in the liver [9]. The cAMP negative cis-
acting element seems in this case to be an inverted CAAT box
[10] binding a factor which could be a member of the nuclear
factor Y (NFY) family [11]. The 5P-£anking DNA of the gene
for malic enzyme contains at least four cis-acting DNA se-
quences that are involved in the negative action of cAMP
acting through the classical PKA signaling pathway. The ma-
jor negative cAMP response element is similar to the consen-
sus binding site for AP1 and binds c-Fos and ATF2 in pres-
ence of cAMP [12]. A fourth example of cAMP-dependent
transcription inhibition involves the rat aldehyde dehydrogen-
ase class-3 gene in which a 66-bp promoter region has been
shown to confer the negative cAMP response. However, nei-
ther the precise cis-acting element nor the cognate trans-acting
factor has been characterized [13].
For the L-PK gene, we have previously demonstrated that
the glucose response element (GlRE) located in the L-PK
promoter, built around two non-canonical E boxes (L4 ele-
ment), functions in close cooperation with a contiguous
HNF4 binding site (L3 element) to assure, in the L-PK con-
text, a full inhibition by cAMP [14]. In addition, we have
more recently shown that the binding activity of the orphan
nuclear receptor HNF4 was decreased by PKA-dependent
phosphorylation [15]. Therefore, the respective role of the
GlRE and the HNF4 binding site in the negative response
to cAMP could be questioned.
In order to gain insight into the negative transcriptional
control of the L-PK expression by cAMP, we have developed
ex vivo analyses by transient transfections in hepatocytes in
primary culture. We show that both GlRE and HNF4 binding
sites of the L-PK promoter are negative cAMP elements
which act synergistically in the natural promoter. PKA-de-
pendent inhibition through HNF4 binding sites requires
HNF4 binding but its precise target (HNF4 itself and/or a
coactivator) remains unknown.
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2. Materials and methods
2.1. Plasmid constructions
All plasmids were constructed by standard DNA cloning proce-
dures and veri¢ed by nucleotide sequencing.
In the Rous sarcoma virus (RSV)/Luci construct, the ¢re£y lucifer-
ase gene is driven by the RSV long terminal repeat (LTR). Restriction
or oligonucleotidic fragments of the L-PK gene corresponding either
to the region 396 or 3183 to +11 nucleotides with respect to the
transcriptional start site were subcloned into the basic plasmid
pGL3 (Promega). The 3150PK/Luci construct was a gift from G.
Rutter [16]. The (L3)3354PK/Luci and (L4)3354PK/Luci constructs
comprise three copies of the L3 box or L4 box, respectively, ligated to
the 354 to +11 proximal base pairs of the L-PK minimal promoter.
The (L4L3)4354PK/Luci construct consists of four copies of the
L4L3 fragment in front of the 354PK minimal promoter. The H4-
105TK/Luci plasmid was a gift from G.U. Ry¡el and has been de-
scribed in Drewes et al. [17]. It consists of four HNF4 binding sites of
the human K1-anti-trypsin gene promoter in front of the 3105 min-
imal promoter of the thymidine kinase gene.
The di¡erent HNF4 cDNAs were cloned into a eukaryotic expres-
sion vector driven by the cytomegalovirus immediate-early promoter
region. The expression vectors for HNF4 wild-type and HNF4 Ala
have been previously described [15]. In the HNF4 Ala mutant, the two
Ser at positions 133 and 134 were replaced by Ala and Gly. Site-
directed mutagenesis of the HNF4 wild-type or HNF4 Ala sequences
was performed by fusion of a two-part PCR ampli¢cation with out-
side primers containing engineered BamHI 5P and EcoRI 3P sites and
internal primers containing the engineered HindIII site (AAG CTT
[Lys Leu]) resulting in the mutants termed HNF4 Leu or HNF4 Leu-
Ala, with respect to the initial matrix, HNF4 wild-type or HNF4 Ala.
In the HNF4 Leu mutant the Arg-Ser residues at positions 303 and
304 are replaced by Lys and Leu. The HNF4 Leu-Ala mutant com-
bines mutations of residues 133, 134 and 303, 304. All mutations and
ligation junctions were con¢rmed by sequencing. The vector coding
for DN-HNF4 was a gift from T. Le¡ [18]. DN-HNF4 is a selective
dominant negative mutant which forms defective heterodimers with
wild-type HNF4, thereby preventing DNA binding and subsequent
transcriptional activation by HNF4.
The expression vector pSVPKA CK, coding for the catalytic CK
subunit of protein kinase A (PKA), was a gift from P. Sassone-Corsi.
The CREB binding protein (CBP) expression vector was a gift from
C.K. Glass and M.G. Rosenfeld. This plasmid contains the complete
coding sequence of the murine CREB binding protein under the con-
trol of the CMV promoter.
2.2. Hepatocyte isolation, cell culture conditions and transfection
Hepatocytes were isolated from male Sprague-Dawley rats (180^
200g) fed with a normal diet by the collagenase perfusion method
[2]. One and a half million freshly isolated hepatocytes were plated
on 6-cm dishes in a ¢nal volume of 3 ml of 199 medium (Gibco)
containing 5 mM glucose supplemented with penicillin, streptomycin,
100 nM insulin, 1 WM triiodothyronine, 1 WM dexamethasone, and 3%
(V/V) fetal calf serum. After 2 h of attachment, the medium was
changed. Hepatocytes were transfected 6 h after isolation. Transfec-
tion was performed by the lipofection method using the DOTAP
transfection reagent (Boehringer Mannheim), according to the manu-
facturer’s instructions. Four microgram of the reporter construct,
alone or with various amounts of expression vectors, or 1 Wg of the
reference RSV/Luci construct were transfected. The pKS Bluescript
vector was used to adjust total amounts of DNA to 5 Wg in each
experiment. The concentrations of expression vectors used were deter-
mined in preliminary experiments as the maximal concentrations be-
fore occurrence of non-speci¢c squelching phenomena. The medium
containing the liposome-DNA complex was replaced 16 h after trans-
fection with hormone-supplemented fresh 199 medium containing
5 mM glucose or 25 mM glucose with or without 0.5 mM 8-bromo-
adenosine 3P, 5P-cyclic monophosphate (cAMP, SIGMA). Hepato-
cytes were harvested 24 h later.
2.3. Luciferase assay
Cellular protein extraction was performed as previously [19]. Luci-
ferase activity was determined as described [20]. Results were normal-
ized with the cellular content determined in each cell extract by a
Bradford assay.
2.4. Data analysis
Statistical analysis was performed by the Student’s t test for un-
paired data using the StatView software. The signi¢cance has been
considered at *P6 0.05, **P6 0.01 or ***P6 0.001.
Fig. 1. Response to glucose, cAMP and PKA catalytic subunit overexpression of various luciferase constructs in hepatocytes in primary culture.
The RSV/Luci construct corresponds to the LTR of RSV in front of the luciferase reporter gene. Boxes L1 to L4 represent the various binding
sites for di¡erent proteins identi¢ed on the L-PK promoter [51]: from 3P to 5P, L1 binds hepatocyte nuclear factor 1, L2 binds nuclear factor
1, L3 binds mainly hepatocyte nuclear factor 4 and also nuclear factor 1, L4 is the GlRE, binding basic/helix-loop-helix/leucine zipper factors,
in particular USFs 1 and 2; other binding activities are currently being characterized. The H4-105TK/Luci construct consists of four HNF4
binding sites of the human K1-anti-trypsin promoter in front of the 3105 minimal promoter of the thymidine kinase gene. The extent of induc-
tion, or inhibition in the case of 3150PK/Luci, by glucose is the ratio between luciferase activities with 25 mM and 5 mM glucose. The extent
of inhibition, or induction in the case of RSV/Luci, by cAMP is the ratio between luciferase activities with 25 mM glucose and 25 mM glucose
plus cAMP. The extent of inhibition by PKA is the ratio between luciferase activities with 25 mM glucose and 25 mM glucose with overexpres-
sion of the catalytic subunit of the PKA (1 Wg). This concentration of expression vector for the catalytic subunit of the PKA (1Wg) increased
the activity of a reporter driven by the rat somatostatin cAMP-response element (CRE) 15-fold (data not shown). Each value represents the
mean of at least ¢ve independent experiments, and are represented þ S.D.
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3. Results
3.1. Both L4 and L3 are negative cAMP response elements
The di¡erent constructs studied were transfected in hepato-
cytes in primary culture, at low (5 mM) or high (25 mM)
glucose, with or without cAMP or PKA catalytic subunit
overexpression. Under these conditions, a control RSV/Luci
plasmid was insensitive to glucose and cAMP (Fig. 1). How-
ever, we veri¢ed that a reporter gene directed by the positive
cAMP response element of the rat somatostatin gene was
activated 10- and 15-fold by cAMP and overexpression of
the PKA catalytic subunit, respectively.
Fig. 2. Trans-acting e¡ects of various wild-type and mutant HNF4 proteins on the activity of the (L3)3354PK/Luci construct in presence and
absence of cAMP. A: Letters in boxes represent the functional domains of nuclear receptors family. The two zinc ¢nger motifs are shown with
the downstream T and A boxes and the activation function 2 domain (AF2). Amino acid sequences around the potential PKA phosphorylation
sites are presented. Numbers indicate amino acids in rat HNF4. Potential PKA phosphorylation sites are underlined. Sequences of the mutated
HNF4 proteins at positions 133- 134 and 303-304 are also presented. Ser133-Ser134 and Arg303-Ser304 were changed to neutral residues and
mutant proteins were termed HNF4 Ala and HNF4 Leu, respectively. The double mutant was termed HNF4 Leu-Ala. Mutated amino acids
are represented with bold letters. wt, wild-type. B: The (L3)3354PK/Luci construct was transfected alone or cotransfected with the indicated
amounts of HNF4 wt, DN-HNF4, HNF4 Ala, HNF4 Leu or HNF4 Leu-Ala expression vectors. The amount of the transfected expression
plasmids was determined from dose-e¡ect experiments and was checked not to result in squelching (data not shown). Hepatocytes were cultured
in the presence of 25 mM glucose with (gray bars) or without (open bars) 0.5 mM 8-bromoadenosine-cAMP. Each value is ‘the mean of at
least three independent experiments, represented þ S.D. * The values obtained in absence of cAMP after overexpression of HNF4wt, HNF4
Ala, HNF4 Leu or HNF4 Leu-Ala, are statistically di¡erent from those without any overexpression (P = 0.0457, P = 0.0404, P = 0.0296 and
P = 0.0363, respectively).
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As previously reported [14^21], the 3183PK construct was
stimulated by glucose about seven-fold and inhibited by
cAMP about 11-fold. The glucose-dependent stimulation
was also totally abolished by cotransfection with the PKA
expression vector (Fig. 1). Constructs devoid of element L4
(the GlRE) were insensitive to glucose, and seemed slightly
inhibited by cAMP, especially the 3150PK/Luci construct
(2.63 þ 1.51 fold inhibition). However, this inhibition was
not statistically signi¢cant compared to the 396PK/Luci con-
struct (1.68 þ 0.63, P = 0.1353). This latter result is in discrep-
ancy with results previously reported by Bergot et al. [14] who
found that 396PK and 3150PK/CAT constructs transfected
in hepatocytes, isolated from a rat that has fasted, and cul-
tured in the absence of glucose and in a serum-free-medium
were stimulated by cAMP instead of being inhibited. The
di¡erent experimental conditions most likely account for these
discordant results. In particular, it could be that serum and
low glucose present in our experimental conditions mimic a
non-speci¢c positive e¡ect of cAMP in serum-free and glu-
cose-free conditions on basal transcription.
We have previously shown that in the context of the natural
L-PK promoter, the presence of both L4 and L3 elements was
required for the positive response to glucose, and therefore for
a negative response to cAMP since this one consists mainly of
inhibition of the glucose-dependent stimulation [14]. However,
a positive response to glucose and partial negative response to
cAMP was conferred on a CAT gene by oligomerized L4
boxes [14]. We now con¢rmed that the (L4)3354PK/Luci
construct was indeed strongly stimulated by glucose (43-
fold) and inhibited by cAMP (36-fold). The only partial
cAMP-dependent inhibition reported by Bergot et al. [14]
was probably due to interference with the non-speci¢c
cAMP stimulatory e¡ect observed in the experimental condi-
tions. In contrast, the (L3)3354PK/Luci construct was almost
insensitive to glucose, which con¢rmed that L4, but not L3, is
the GlRE (Fig. 1). However, this L3-dependent construct was
inhibited about six-fold by both cAMP and PKA overexpres-
sion. The construct directed by oligomerized L4L3 elements
was stimulated by glucose and inhibited by cAMP in the same
proportions (about 50-fold) as the construct directed only by
oligomerized L4 elements (Fig. 1).
3.2. HNF4-dependent transactivation is inhibited by cAMP and
PKA
To con¢rm that oligomerized HNF4 binding sites constitute
intrinsically negative cAMP response elements, we used a re-
porter gene directed by four HNF4 binding sites from the K1-
anti-trypsin gene promoter (H4-105TK/Luci construct) [17].
This construct was inhibited about eight-fold by both cAMP
and overexpression of the PKA catalytic subunit (Fig. 1). In
order to verify that the inhibited activity required HNF4 bind-
ing on its cognate sites, we looked at the e¡ect of HNF4
overexpression on cAMP-dependent inhibition. While the
(L3)3354PK/Luci construct was only slightly (but signi¢-
cantly for P6 0.05) stimulated by HNF4 overexpression,
probably because hepatocytes already contain a high endoge-
nous HNF4 level, it was still inhibited by cAMP to the same
extent as in the absence of HNF4 expression vector (Fig. 2B).
Overexpression of a HNF4 negative transdominant mutant,
DN-HNF4, which prevents formation of active HNF4 homo-
dimers, resulted in inhibition of the basal promoter activity
and suppressed any further negative e¡ect of cAMP (Fig. 2B).
These results indicate that the transcriptional activity inhib-
ited by cAMP requires binding of HNF4 to its cognate sites.
3.3. Mutant HNF4 variants whose PKA phosphorylation sites
have been mutated still confer HNF4-dependent cAMP-
mediated inhibition of the (L3)3354PK/Luci construct
We have recently shown that the binding of HNF4 was
decreased by PKA-dependent phosphorylation. Therefore, to
test the hypothesis that inhibition of the (L3)3354PK con-
struct by cAMP could be due to inhibition of the HNF4
binding activity by PKA-dependent phosphorylation, we in-
vestigated activity and response to cAMP of the (L3)3354PK
reporter cotransfected with an expression vector for the pre-
viously described HNF4 Ala mutant [15] whose consensus
PKA-dependent phosphorylation site at position 133^134
has been mutated (Fig. 2A). This mutant is insensitive to
inhibition of its DNA binding activity after in vitro phospho-
rylation by the PKA catalytic subunit [15]. We also tested the
e¡ect of a mutation of another putative PKA-dependent
phosphorylation site (301-RLRS-304) conserved among mam-
mals, alone (HNF4 Leu), or in association with the former
mutation (HNF4 Leu-Ala) (Fig. 2A). In fact, Fig. 2B shows
that all three HNF4 variants transactivated the (L3)3354PK/
Luci construct to the same extent as the wild-type and re-
mained sensitive to the negative action of cAMP. Thus, these
results indicate that the putative PKA-dependent phosphoryl-
ation sites of HNF4 do not play a crucial role in the negative
regulation of the HNF4 activity by cAMP in hepatocytes in
primary culture.
3.4. CREB binding protein (CBP) is a coactivator of HNF4
CBP has been demonstrated to be a coactivator of HNF4
[22]. In order to determine whether CBP could be implicated
in the inhibition of the (L3)3354PK/Luci construct by cAMP,
we have cotransfected this reporter plasmid with a CBP ex-
pression vector. Overexpression of CBP produced a four-fold
Fig. 3. E¡ect of a CBP overexpression on the 396PK/Luci and
(L3)3354PK/Luci constructs activities. The 396PK/Luci and
(L3)3354PK/Luci constructs were either transfected alone or co-
transfected with 250 ng of the CBP expression vector. The amount
of the transfected CBP expression plasmid was determined from
dose-e¡ect experiments (data not shown). Hepatocytes were cultured
in the presence of 25 mM glucose with (gray bars) or without (open
bars) 0.5 mM 8-bromoadenosine-cAMP. Each value is the mean of
three experiments, shown þ S.D.
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stimulation of the HNF4-dependent construct while it had no
e¡ect on a construct devoid of HNF4 binding site, the 96PK/
Luci plasmid, demonstrating the speci¢city of the CBP action.
However, the CBP e¡ect remained sensitive to cAMP inhi-
bition (Fig. 3). Thus, in hepatocytes in primary culture, we
con¢rm that CBP is a HNF4 coactivator but is unable to
reverse cAMP-dependent inhibition.
4. Discussion
While the stimulation of gene transcription by cAMP is
very well documented, much less is known about negative
regulation of gene expression by this second messenger. Tran-
scription of the L-PK gene is stimulated by glucose and in-
hibited by glucagon acting through its second messenger,
cAMP. The inhibition of the L-PK gene by cAMP was shown
to involve the classical PKA signaling pathway since the
cAMP e¡ect could be reproduced by overexpression of the
PKA catalytic subunit [21]. We have previously shown that
the in vivo transcriptional inhibition by glucagon of glucose
responsive genes in the liver was a very rapid phenomenon,
detectable in only a few minutes by run-on transcription as-
says [1], contrasting with the activation by glucose which is
delayed for several hours [23]. In addition, Tanaka’s group
has reported that transcriptional activation of the L-PK gene
by glucose was inhibited by cycloheximide while cAMP-medi-
ated inhibition was insensitive to this translational inhibitor
[24]. Consequently, the cAMP action is most likely explained
by a post-translational event mediated by PKA, tentatively a
direct or indirect phosphorylation of transcription factors. In-
deed, indirect transcriptional e¡ects, for instance inhibition of
the glucokinase gene by cAMP [25], would not be so rapid in
inhibiting transcription of downstream genes and would be
expected to be sensitive to cycloheximide. The goal of the
present study was to ¢rmly identify the negative cAMP re-
sponse elements in the L-PK gene promoter, in particular to
determine the respective role of the L4 and L3 elements in this
response.
While, as previously reported [14], the L4-dependent con-
struct, but not the L3-dependent one, was positively regulated
by glucose, both constructs were inhibited by cAMP or over-
expression of the PKA catalytic subunit. Therefore, the
cAMP/PKA signaling pathway seems to be able to down-reg-
ulate transactivation mediated by both the glucose-response
complex assembled on L4, i.e. the GlRE and the L3 complex.
The fact that the (L4L3) oligomeric construct does not exhibit
a higher response to both agents than the L4 oligomeric con-
struct suggests that L4 is the main target of the two signaling
pathways.
The glucose response complex is able to bind members of
the basic-helix-loop-helix-leucine zipper family, especially up-
stream stimulatory factors (USFs). While we provided evi-
dence in vivo and ex vivo for the role of the USFs in the
glucose response [16,19,26,27], this point is still disputed by
others [28]. In addition, we [29] and others [30] are currently
studying the putative role of other partners of the complex,
such that the exact targets of the cAMP pathway in this com-
plex still can not be determined.
For the L3 complex, HNF4 is an obvious candidate target
for cAMP/PKA-dependent inhibition. Indeed, we show in this
paper that a reporter gene directed by an oligomerized HNF4
binding site di¡erent from L3 (i.e. the K1-anti-trypsin gene
promoter site) was also inhibited by cAMP. Overexpression
of HNF4, which prevents that the element L3 becomes occu-
pied by a di¡erent DNA binding factor, does not impair
cAMP-dependent inhibition, while the very low activity of
the L3-dependent construct co-transfected with an expression
vector for a negative transdominant HNF4 mutant appears to
be insensitive to cAMP. Viollet et al. have recently shown that
HNF4 can be phosphorylated on the A-box by cAMP-de-
pendent protein kinase A resulting in decrease of its DNA-
binding activity [15]. However, surprisingly, neither a A-box
HNF4 mutant (HNF4 Ala), nor other mutants whose other
putative PKA phosphorylation site located more downstream
has been mutated, alone (HNF4 Leu) or in conjunction with
the Ala A-box mutation (HNF4 Leu-Ala), were able, when
overexpressed, to impair the cAMP negative action on the L3-
dependent construct in transfected hepatocytes. This suggests
that the decreased binding activity of HNF4 phosphorylated
on the A-box PKA-phosphorylation site (and perhaps on the
more downstream putative site) plays no detectable role when
tested on oligomerized L3 sites in hepatocytes. It may be that
cooperative binding on oligomerized sites compensates for
decreased binding activity. In addition, our results indicate
that cAMP and PKA can decrease HNF4-mediated transac-
tivation by another means than direct phosphorylation of
consensus PKA phosphorylation sites. It is conceivable that
PKA acts indirectly through a cascade of phosphorylation
events modifying other sites known to be multiple in HNF4
[31] or through HNF4 partners, coactivators or corepressors
[32^34]. In the present work, we focused on a possible impli-
cation of CBP. Indeed, the well known CBP/p300 factor is a
coactivator integrating many di¡erent transduction pathways
and is able to synergize HNF4 transcriptional action through
two physically separated domains [22]. Our experiments show
that CBP overexpression stimulates the L3-dependent con-
struct four-fold, con¢rming the crucial role played by CBP
in the transcriptional activity of HNF4 in hepatocytes. An
hypothesis could be that the PKA signaling pathway may
inhibit HNF4-mediated transcription by phosphorylating pro-
teins, such as CREB, which compete for limiting amounts of
the coactivator CBP, as it has been demonstrated for cAMP
inhibition of NF-UB-mediated transcription [35]. However, in
our system, the induction by CBP of the L3-dependent con-
struct remains sensitive to cAMP inhibition, therefore pre-
cluding the hypothesis of nuclear competition for limiting
amounts of CBP. Phosphorylation of CBP/p300 by PKA is
well documented [36] but has generally been involved in the
transcriptional activation by cAMP [36^38]. Indeed, cAMP-
dependent phosphorylation of both CREB and CBP increases
their interaction and resulting transactivation [39^41]. How-
ever, it cannot be ruled out that interaction between HNF4
and CBP is inhibited by CBP phosphorylation.
It is also noteworthy to recall that HNF4 has also been
demonstrated to be a trans-acting factor of genes transcrip-
tionally stimulated by cAMP, such as the phosphoenolpyru-
vate carboxykinase and tyrosine aminotransferase [42^44]. In
both cases the cAMP e¡ect is mediated by the CREB activa-
tor, associated with C/EBPK formerly [45^47]. Therefore, it
could be that HNF4 is by itself insu⁄cient, when bound to
a single site, to impose on a promoter a negative response to
cAMP; it could rather act synergistically with other regula-
tory complexes, e.g. the GlRE complex in the L-PK gene.
In conclusion, the identi¢cation in the L-PK gene promoter
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of two negative cAMP response elements binding di¡erent
transcriptional complexes, con¢rms the multiplicity of the
possible mechanisms of the cAMP-dependent transcriptional
controls, activation [5,6,45^50] as well as inhibition [8^13].
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